New innovative clinical services to help pharmaceutical and biotech companies improve patient recruitment, reduce the risk of adverse reactions, and…
The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to ProgressPlanning for APVO436 Phase 2…
Net revenue increased 5% in Q3 2023 versus Q2 2023Top line results expected before Thanksgiving for company's phase 3 OnTarget…
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for…
FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today…
SPARKS, NV / ACCESSWIRE / November 14, 2023 / Ludwig Enterprises, Inc., (OTC PINK:LUDG), a developer and provider of innovative…
SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of…
Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues…
Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts…
Announced global Phase 1 clinical trial design of TERN-701 (allosteric BCR-ABL) for CML with patient screening anticipated in December 2023…